Therefore, interfering with Wnt or S1p signaling during treatment of infectious and neurodegenerative diseases as well as anti-cancer therapy remains a major clinical obstacle as adverse effects and cross-reactions are not well predictable30,53–55. This evidence concerns the gene MBTPS1 and neurodegenerative disease.